Neuromuscular stimulator enters US trial:
This article was originally published in Clinica
Executive Summary
NeuroControl has begun a multi-centre clinical trial in the US to assess its minimally invasive neuromuscular stimulator for treating shoulder pain in patients who have suffered a stroke. The StIM system is a miniaturised, multi-channel, programmable device designed to reduce shoulder pain and subluxation - the separation of the shoulder joint due to weak muscles. It delivers therapeutic stimulation through electrodes placed in the shoulder muscles. The Cleveland, Ohio based company CE-marked the StIM device for sale in Europe in January (see Clinica No 892, p 25).
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.